免疫检查点抑制剂（ICIs）在临床研究和实践中取得了显着的成功。值得注意的是，肝转移对 ICI 不敏感。肝脏局部治疗可以对肿瘤细胞造成不可逆的损伤并释放肿瘤抗原，从而为肝转移的免疫治疗提供依据。 ICI 与局部治疗的联合治疗对于肝转移患者来说是一个有前途的选择。临床前研究表明，ICIs与局部治疗相结合可产生显着的协同抗肿瘤作用。然而，目前 ICI 联合局部治疗的疗效证据仍然不足。因此，我们对局部治疗肝转移的机制及其与ICIs联合治疗的临床研究进展进行综述。© 2024。作者。

Immune checkpoint inhibitors (ICIs) have achieved remarkable success in clinical research and practice. Notably, liver metastasis is not sensitive to ICIs. Liver locoregional therapies can cause irreversible damage to tumor cells and release tumor antigens, thereby providing a rationale for immunotherapy treatments in liver metastasis. The combination therapy of ICIs with locoregional therapies is a promising option for patients with liver metastasis. Preclinical studies have demonstrated that combining ICIs with locoregional therapies produces a significantly synergistic anti-tumor effect. However, the current evidence for the efficacy of ICIs combined with locoregional therapies remains insufficient. Therefore, we review the literature on the mechanisms of locoregional therapies in treating liver metastasis and the clinical research progress of their combination with ICIs.© 2024. The Author(s).